Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
540 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Follicular Lymphoma - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Follicular Lymphoma - Pipeline Review, H2 2016, provides an overview of the Follicular Lymphoma (Oncology) pipeline landscape. Follicular lymphoma is a common type of non-Hodgkin Lymphoma (NHL). It is a slow-growing lymphoma that arises from B-cells, a type of white blood cell. It is also called an "indolent" or "low-grade" lymphoma for its slow nature. Follicular lymphoma mainly affects older adults. Enlargement of lymph nodes is a common symptom. Fever, weight loss, sweating and fatigue are other symptoms of lymphoma. There are different types of treatment for patients with follicular lymphoma such as surgery, radiation therapy, and chemotherapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Follicular Lymphoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Follicular Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Follicular Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Follicular Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 10, 46, 29, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 1 molecules, respectively.Follicular Lymphoma. Follicular Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Follicular Lymphoma (Oncology). - The pipeline guide reviews pipeline therapeutics for Follicular Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Follicular Lymphoma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Follicular Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Follicular Lymphoma (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Follicular Lymphoma (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Follicular Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 6 Follicular Lymphoma Overview 7 Therapeutics Development 8 Follicular Lymphoma - Therapeutics under Development by Companies 10 Follicular Lymphoma - Therapeutics under Investigation by Universities/Institutes 15 Follicular Lymphoma - Pipeline Products Glance 16 Follicular Lymphoma - Products under Development by Companies 19 Follicular Lymphoma - Products under Investigation by Universities/Institutes 25 Follicular Lymphoma - Companies Involved in Therapeutics Development 26 Follicular Lymphoma - Therapeutics Assessment 83 Drug Profiles 97 Follicular Lymphoma - Dormant Projects 507 Follicular Lymphoma - Discontinued Products 510 Follicular Lymphoma - Product Development Milestones 511 Appendix 528
List of Tables
Number of Products under Development for Follicular Lymphoma, H2 2016 19 Number of Products under Development for Follicular Lymphoma - Comparative Analysis, H2 2016 20 Number of Products under Development by Companies, H2 2016 22 Number of Products under Development by Companies, H2 2016 (Contd..1) 23 Number of Products under Development by Companies, H2 2016 (Contd..2) 24 Number of Products under Development by Companies, H2 2016 (Contd..3) 25 Number of Products under Investigation by Universities/Institutes, H2 2016 26 Comparative Analysis by Late Stage Development, H2 2016 27 Comparative Analysis by Clinical Stage Development, H2 2016 28 Comparative Analysis by Early Stage Development, H2 2016 29 Products under Development by Companies, H2 2016 30 Products under Development by Companies, H2 2016 (Contd..1) 31 Products under Development by Companies, H2 2016 (Contd..2) 32 Products under Development by Companies, H2 2016 (Contd..3) 33 Products under Development by Companies, H2 2016 (Contd..4) 34 Products under Development by Companies, H2 2016 (Contd..5) 35 Products under Investigation by Universities/Institutes, H2 2016 36 Follicular Lymphoma - Pipeline by AbbVie Inc, H2 2016 37 Follicular Lymphoma - Pipeline by Affimed GmbH, H2 2016 38 Follicular Lymphoma - Pipeline by Amgen Inc, H2 2016 39 Follicular Lymphoma - Pipeline by Asana BioSciences LLC, H2 2016 40 Follicular Lymphoma - Pipeline by Bayer AG, H2 2016 41 Follicular Lymphoma - Pipeline by BeiGene Ltd, H2 2016 42 Follicular Lymphoma - Pipeline by Bio-Path Holdings Inc, H2 2016 43 Follicular Lymphoma - Pipeline by Biocon Ltd, H2 2016 44 Follicular Lymphoma - Pipeline by Biogen Inc, H2 2016 45 Follicular Lymphoma - Pipeline by Biogenomics Limited, H2 2016 46 Follicular Lymphoma - Pipeline by Biothera Pharmaceutical Inc, H2 2016 47 Follicular Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 48 Follicular Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2016 49 Follicular Lymphoma - Pipeline by Celgene Corp, H2 2016 50 Follicular Lymphoma - Pipeline by Celldex Therapeutics Inc, H2 2016 51 Follicular Lymphoma - Pipeline by Celltrion Inc, H2 2016 52 Follicular Lymphoma - Pipeline by Cellular Biomedicine Group Inc, H2 2016 53 Follicular Lymphoma - Pipeline by Coherus BioSciences Inc, H2 2016 54 Follicular Lymphoma - Pipeline by Constellation Pharmaceuticals Inc, H2 2016 55 Follicular Lymphoma - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 56 Follicular Lymphoma - Pipeline by CTI BioPharma Corp, H2 2016 57 Follicular Lymphoma - Pipeline by Curis Inc, H2 2016 58 Follicular Lymphoma - Pipeline by Dynavax Technologies Corp, H2 2016 59 Follicular Lymphoma - Pipeline by Eisai Co Ltd, H2 2016 60 Follicular Lymphoma - Pipeline by EpiZyme Inc, H2 2016 61 Follicular Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 62 Follicular Lymphoma - Pipeline by Genentech Inc, H2 2016 63 Follicular Lymphoma - Pipeline by Gilead Sciences Inc, H2 2016 64 Follicular Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2016 65 Follicular Lymphoma - Pipeline by Hutchison MediPharma Ltd, H2 2016 66 Follicular Lymphoma - Pipeline by Immune Design Corp, H2 2016 67 Follicular Lymphoma - Pipeline by ImmunoGen Inc, H2 2016 68 Follicular Lymphoma - Pipeline by Immunomedics Inc, H2 2016 69 Follicular Lymphoma - Pipeline by Johnson & Johnson, H2 2016 70 Follicular Lymphoma - Pipeline by Juno Therapeutics Inc, H2 2016 71 Follicular Lymphoma - Pipeline by Karyopharm Therapeutics Inc, H2 2016 72 Follicular Lymphoma - Pipeline by Kite Pharma Inc, H2 2016 73 Follicular Lymphoma - Pipeline by MedImmune LLC, H2 2016 74 Follicular Lymphoma - Pipeline by Medivation Inc, H2 2016 75 Follicular Lymphoma - Pipeline by MEI Pharma Inc, H2 2016 76 Follicular Lymphoma - Pipeline by Merck & Co Inc, H2 2016 77 Follicular Lymphoma - Pipeline by Merck KGaA, H2 2016 78 Follicular Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 79 Follicular Lymphoma - Pipeline by Mirati Therapeutics Inc, H2 2016 80 Follicular Lymphoma - Pipeline by MorphoSys AG, H2 2016 81 Follicular Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2016 82 Follicular Lymphoma - Pipeline by Novartis AG, H2 2016 83 Follicular Lymphoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 84 Follicular Lymphoma - Pipeline by Pfizer Inc, H2 2016 85 Follicular Lymphoma - Pipeline by Pharmacyclics Inc, H2 2016 86 Follicular Lymphoma - Pipeline by Portola Pharmaceuticals Inc, H2 2016 87 Follicular Lymphoma - Pipeline by Rhizen Pharmaceuticals SA, H2 2016 88 Follicular Lymphoma - Pipeline by Sandoz International GmbH, H2 2016 89 Follicular Lymphoma - Pipeline by Seattle Genetics Inc, H2 2016 90 Follicular Lymphoma - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 91 Follicular Lymphoma - Pipeline by TG Therapeutics Inc, H2 2016 92 Follicular Lymphoma - Pipeline by Verastem Inc, H2 2016 93 Assessment by Monotherapy Products, H2 2016 94 Assessment by Combination Products, H2 2016 95 Number of Products by Stage and Target, H2 2016 97 Number of Products by Stage and Mechanism of Action, H2 2016 101 Number of Products by Stage and Route of Administration, H2 2016 105 Number of Products by Stage and Molecule Type, H2 2016 107 Follicular Lymphoma - Dormant Projects, H2 2016 518 Follicular Lymphoma - Dormant Projects (Contd..1), H2 2016 519 Follicular Lymphoma - Dormant Projects (Contd..2), H2 2016 520 Follicular Lymphoma - Discontinued Products, H2 2016 521
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
